Staus Dean P, Strachan Ryan T, Manglik Aashish, Pani Biswaranjan, Kahsai Alem W, Kim Tae Hun, Wingler Laura M, Ahn Seungkirl, Chatterjee Arnab, Masoudi Ali, Kruse Andrew C, Pardon Els, Steyaert Jan, Weis William I, Prosser R Scott, Kobilka Brian K, Costa Tommaso, Lefkowitz Robert J
Nature. 2016 Jul 21;535(7612):448-52. doi: 10.1038/nature18636. Epub 2016 Jul 13.
G-protein-coupled receptors (GPCRs) modulate many physiological processes by transducing a variety of extracellular cues into intracellular responses. Ligand binding to an extracellular orthosteric pocket propagates conformational change to the receptor cytosolic region to promote binding and activation of downstream signalling effectors such as G proteins and β-arrestins. It is well known that different agonists can share the same binding pocket but evoke unique receptor conformations leading to a wide range of downstream responses (‘efficacy’). Furthermore, increasing biophysical evidence, primarily using the β2-adrenergic receptor (β2AR) as a model system, supports the existence of multiple active and inactive conformational states. However, how agonists with varying efficacy modulate these receptor states to initiate cellular responses is not well understood. Here we report stabilization of two distinct β2AR conformations using single domain camelid antibodies (nanobodies)—a previously described positive allosteric nanobody (Nb80) and a newly identified negative allosteric nanobody (Nb60). We show that Nb60 stabilizes a previously unappreciated low-affinity receptor state which corresponds to one of two inactive receptor conformations as delineated by X-ray crystallography and NMR spectroscopy. We find that the agonist isoprenaline has a 15,000-fold higher affinity for β2AR in the presence of Nb80 compared to the affinity of isoprenaline for β2AR in the presence of Nb60, highlighting the full allosteric range of a GPCR. Assessing the binding of 17 ligands of varying efficacy to the β2AR in the absence and presence of Nb60 or Nb80 reveals large ligand-specific effects that can only be explained using an allosteric model which assumes equilibrium amongst at least three receptor states. Agonists generally exert efficacy by stabilizing the active Nb80-stabilized receptor state (R80). In contrast, for a number of partial agonists, both stabilization of R80 and destabilization of the inactive, Nb60-bound state (R60) contribute to their ability to modulate receptor activation. These data demonstrate that ligands can initiate a wide range of cellular responses by differentially stabilizing multiple receptor states.
G蛋白偶联受体(GPCRs)通过将多种细胞外信号转导为细胞内反应来调节许多生理过程。配体与细胞外正构口袋结合后,构象变化会传播到受体的胞质区域,以促进下游信号效应器(如G蛋白和β-arrestin)的结合和激活。众所周知,不同的激动剂可以共享相同的结合口袋,但会引发独特的受体构象,从而导致广泛的下游反应(“效能”)。此外,越来越多的生物物理证据(主要以β2肾上腺素能受体(β2AR)作为模型系统)支持多种活性和非活性构象状态的存在。然而,具有不同效能的激动剂如何调节这些受体状态以引发细胞反应,目前尚不清楚。在这里,我们报告了使用单域骆驼科抗体(纳米抗体)稳定两种不同的β2AR构象——一种先前描述的正变构纳米抗体(Nb80)和一种新鉴定的负变构纳米抗体(Nb60)。我们表明,Nb60稳定了一种先前未被认识到的低亲和力受体状态,该状态对应于X射线晶体学和核磁共振光谱所描绘的两种非活性受体构象之一。我们发现,与Nb60存在时异丙肾上腺素对β2AR的亲和力相比,在Nb80存在的情况下,激动剂异丙肾上腺素对β2AR的亲和力高15000倍,突出了GPCR的完整变构范围。评估17种不同效能的配体在不存在和存在Nb60或Nb80的情况下与β2AR的结合,发现了很大的配体特异性效应,这只能使用一种变构模型来解释,该模型假设至少三种受体状态之间存在平衡。激动剂通常通过稳定活性的、由Nb80稳定的受体状态(R80)来发挥效能。相比之下,对于一些部分激动剂,R80的稳定和非活性的、与Nb60结合的状态(R60)的不稳定都有助于它们调节受体激活的能力。这些数据表明,配体可以通过差异稳定多种受体状态来引发广泛的细胞反应。